Depo-Medrone 40mg/ml with Lidocaine 10mg/ml Suspension for Injection, 2ml Vial *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 February 2021

File name

DEC202002474_Reg HCP leaflet DML 18_1 & PIL DML 19_2 IE clean_1613137652.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 11 February 2021

File name

DEC202109158_Reg HCP leaflet DM 22_1 PIL DM 24_1 IE clean_1613050454.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals
  • Correction of spelling/typing errors

Updated on 16 January 2020

File name

DEC202002474_Reg HCP leaflet DML 18_1 & PIL DML 19_2 IE clean_1579181775.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 16 January 2020

File name

DEC202002474_Reg SPC DML 18_3 2ml IE clean_1579169768.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following changes to the labelling have been approved. Please refer to attached copy/copies of labelling documentation for full details.

The SPC has been updated as follows: Sections 4.4 to add information about peritonitis; section 4.6 to add information on low birth weight, relationship to dose and impairment of fertility; 4.5 to remove a cautionary statement about the use of aspirin and corticosteroids in patients with hypoprothrombinemia; 4.8 to add peritonitis and anaphylactoid reaction as well as PT updates; 5.2 to add PK information pertaining to lidocaine; and 5.3 to add information concerning impairment of fertility, carcinogenesis, mutagenesis, embryo-foetal lethality, and details from animal studies. Changes in line with CDS.

Updated on 10 April 2019

File name

DEC201918654_Reg HCP leaflet DML 17_1 & PIL DML 18_1 IE clean_1554881512.pdf

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 26 September 2018

File name

Reg SPC DML 17_1 2ml IE cl_1537965143.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:


IE DML 027 - CDS revised to align with the information across the corticosteroid CDSs

IE DML 029 - CDS revised to include a warning for Epidural lipomatosis & Central serous chorioretinopathy. Updates also regarding use of intrathecal/epidural routes of administration and to align with the information across the corticosteroid CDSs.

IE DML 031 - CDS was revised to include a warning for Pheochromocytoma.

IE DML 034 - CDS was updated to include warnings for benzyl alcohol and to separate information for methylprednisolone acetate and lidocaine throughout SPC

IE DML 037 – CDS was updated to add statement re discouraging use of high doses of corticosteroids to treat traumatic brain injury and impairment of fertility. Also to add information re pharmacokinetic properties and pre-clinical safety data.

IE DM 042 – CDS was updated to add warning concerning thrombosis including venous thromboembolism and to add thrombosis and pulmonary embolism as new ADRs. Also to remove the term ‘high doses’ from the statement regarding treatment of traumatic brain injury.

IE DM 047 – SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00002026-201411. Update was included in IE DML 034 and 037 updates.

IE DML 053 - SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00000449-201604

Updated on 29 August 2018

File name

Reg SPC DM 20_1 2ml IE cl_1535527647.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

IE DM 025 - CDS revised to align with the information across the corticosteroid CDSs, and to fulfil PSUR commitment (to update the SPC with reference to Kaposi’s Sarcoma and to reformat section 4.8 of the SPCs.)

IE DM 029 - CDS revised to align with the information across the corticosteroid CDSs.

IE DM 031 - CDS was revised to include a warning for Pheochromocytoma.

IE DM 033 - CDS was updated to include warnings for benzyl alcohol.

IE DM 036 – CDS was updated to add statement re discouraging use of high doses of corticosteroids to treat traumatic brain injury.

IE DM 037 – CDS was updated to add warning concerning thrombosis including venous thromboembolism and to add thrombosis and pulmonary embolism as new ADRs.

IE DM 042 – SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00002026-201411

IE DM 048 - CDS was updated to add a cautionary statement about use in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

IE DM 049 - SPC was updated in line with PRAC updates: methylprednisolone PSUSA-00000449-201604

Updated on 09 August 2018

File name

Reg HCP leaflet DML 17_1 PIL DML 17_1 IE cl_1533813190.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - dose and frequency
  • Change to section 3 - duration of treatment
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 09 August 2018

File name

Reg SPC DML 17_1 1ml IE cl_1533811975.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

VAR II CDS update (s4.2, 4.3, 4.4, 5.4, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3); 2012-0001342

 

VAR II CDS update (s4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.2, 5.3); 2013-001977, 2013-0002862

 

VAR II CDS update (s4.4); 2013-0003195

 

VAR II CDS update (s4.2, 4.4, 4.6, 4.8, 4.9, 5.1, 5.2); 3013-0004235

 

VAR II CDS update (s4.4, 4.6, 5.2, 5.3); 2014-0005478, 2014-0005532, 2014-0005135

 

VAR II CDS update (s4.4, 4.8); 2014-0007607, 2014-0007608

 

VAR IB PRAC update (s4.4, 4.8); 2015-0013452

 

VAR II CDS update (s4.4, 4.8); 2018-0036511

Updated on 06 June 2018

File name

Red_SPC_DML_2ml_15_1_IE_clean.docx

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 - Special warnings and precautions for use

Updated on 30 April 2018

File name

Red_SPC_DML_2ml_15_1_IE_clean.docx

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

s4.4 Special warnings and precautions for use

Addition of a cautionary statement about use in patients with systemic sclerosis as increased incidence of scleroderma renal crisis observed with corticosteroids, including methylprednisolone

Updated on 26 April 2018

File name

Reg HCP leaflet DML 15_1 & PIL DML 15_1 IE clean.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 05 April 2017

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 05 April 2017

File name

PIL_11140_874.pdf

Reasons for updating

  • New PIL for new product

Updated on 04 April 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 October 2012

Reasons for updating

  • Change of licence holder
  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 18 October 2011

Reasons for updating

  • Change to marketing authorisation holder

Updated on 10 August 2011

Reasons for updating

  • Change to date of revision
  • Correction of spelling/typing errors

Updated on 15 June 2011

Reasons for updating

  • Change due to user-testing of patient information

Updated on 23 July 2010

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 07 February 2007

Reasons for updating

  • Change from the BAN of the active substance to the rINN

Updated on 26 July 2006

Reasons for updating

  • New PIL for medicines.ie